Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Duan, Wenrui ^a   Gao, Li ^a   Wu, Xin ^a   Hade, Erinn M ^a   Gao, Jian Xin ^a   Ding, Haiming ^a   Barsky, Sanford H ^a   Otterson, Gregory A ^a   Villalona Calero, Miguel A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; PROTEIN P53; SURFACTANT PROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER CELL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; GAMMA IRRADIATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LUNG ALVEOLUS CELL TYPE 2; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PROMOTER REGION; PROTEIN METHYLATION; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE; AGING; ANIMAL; CELL CYCLE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY;

ANIMALIA; MUS; MUS MUSCULUS;

AGING; ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENE EXPRESSION REGULATION; GENES, RAS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65949093956     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005563     Document Type: Article

References (67)

1. Alberg AJ, Brock MV, Samet JM (2005) Epidemiology of lung cancer: Looking to the future. J Clin Oncol 23: 3175-3185.
2. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, et al. (2007) American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 25: 146-162.
3. Takahashi T (2002) Lung cancer: an ever increasing store of in-depth basic knowledge and the beginning of its clinical application. Oncogene 21: 6868-6869.
4. D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, et al. (1992) High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7: 339-346.
5. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, et al. (1992) p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171-180.
6. Hernandez-Boussard TM, Hainaut P (1998) A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ Health Perspect 106: 385-391.
7. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P (1999) IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. Hum Mutat 14: 1-8.
8. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, et al. (2002) The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614.
9. Bargonetti J, Reynisdottir I, Friedman PN, Prives C (1992) Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 6: 1886-1898.
10. Farmer GE, Bargonetti J, Zhu H, Friedman P, Prywes R, et al. (1992) Wild-type p53 activates transcription in vitro. Nature 358: 83-86.
11. Kern SE, Pietelpol JA, Thiagalingam S, Seymour A, Kinzler KW, et al. (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-830.
12. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK (1993) Gain of function mutations in p53. Nat Genet 4: 42-46.
13. Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788-6793.
14. Chumakov AM, Miller CW, Chen DL, Koeffler HP (1993) Analysis of p53 transactivation through high-affinity binding sites. Oncogene 8: 3005-3011.
15. Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M, et al. (1996) The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Oncogene 12: 2361-2367.
16. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, et al. (1994) Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9: 1899-1906.
17. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB (1993) Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8: 2555-2559.
18. Albor A, Kaku S, Kulesz-Martin M (1998) Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants. Cancer Res 58: 2091-2094.
19. Wu L, Bayle JH, Elenbaas B, Pavletich NP, Levine AJ (1995) Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol 15: 497-504.
20. Blandino G, Levine AJ, Oren M (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485.
21. El-Hizawi S, Lagowski JP, Kulesz-Martin M, Albor A (2002) Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res 62: 3264-3270.
22. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
23. Duan W, Ding H, Subler MA, Zhu WG, Zhang H, et al. (2002a) Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene 21: 7831-7838.
24. Duan W, Ding H, Zhu WG, Srinivasan K, Otterson GA, et al. (2002b) RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. Biotechniques 33: 58-66.
25. Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908.
26. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, et al. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221.
27. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, et al. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708.
28. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
29. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, et al. (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17: 4657-4667.
30. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK (1990) Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A 87: 5863-5867.
31. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR (1991) Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A 88: 5006-5010.
32. Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, et al. (1992) p53 mutations occur in aggressive breast cancer. Cancer Res 52: 3918-3923.
33. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, et al. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48: 5738-5741.
34. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW (1989) Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci U S A 86: 3070-3074.
35. Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ (1995) CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 11: 1211-1216.
36. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, et al. (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 95: 11891-11896.
37. Wang Y, Zhang Z, Lubet R, You M (2005) Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. Oncogene 24: 3042-3049.
38. Chen J, Wu X, Lin J, Levine AJ (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445-2452.
39. Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, et al. (1998) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 12: 2658-2663.
40. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
41. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303.
42. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, et al. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
43. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
44. Picksley SM, Lane DP (1993) The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15: 689-690.
45. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, et al. (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557.
46. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
47. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
48. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10: 1054-1072.
49. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
50. van Oijen MG, Slootweg PJ (2000) Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 6: 2138-2145.
51. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
52. Milner J, Medcalf EA, Cook AC (1991) Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol 11: 12-19.
53. Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, vanOostrom CT, et al. (2007) Dominant-negative but not gain-of-function effects of a p53. R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res 67: 4648-4656.
54. Duan W, Gao L, Jin D, Otterson GA, Villalona-Calero MA (2008) Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice. Transgenic Res 17: 355-366.
55. Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, et al. (2005) DNA repair, genome stability, and aging. Cell 120: 497-512.
56. Busuttil R, Bahar R, Vijg J (2007) Genome dynamics and transcriptional deregulation in aging. Neuroscience 145: 1341-1347.
57. Duan W, Gao L, Druhan LJ, Zhu WG, Morrison C, et al. (2004) Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst 96: 1718-1721.
58. Liu Y, An Q, Li L, Zhang D, Huang J, et al. (2003) Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 24: 1897-1901.
59. Atwal GS, Rabadán R, Lozano G, Strong LC, Ruijs MWG, et al. (2008) An Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients. PLoS ONE 3(4): e1951.
60. Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, et al. (2008) Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors. PLoS ONE 3(1): e1373.
61. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanière P, et al. (2005) TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65: 5076-5083.
62. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, et al. (2008) Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 3: e1651.
63. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, et al. (2001) Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 86-91.
64. Hosmer DW, Lemeshow S (2000) Applied Logistic Regression, Second Edition John Wiley & Sons.
65. Holm S (1979) A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6: 65-70.
66. Sankoh AJ, Huque MF, Dubey SD (1979) Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16: 2529-2542.
67. StataCorp (2007) Stata Statistical Software: Release 10. College Station, TX.